董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| David Cory | 男 | Chief Executive Officer, Director | 61 | 未披露 | 未持股 | 2025-11-17 |
| Thomas Folinsbee | 男 | Independent Director | 57 | 未披露 | 未持股 | 2025-11-17 |
| 苏震波 | 男 | Independent Director | 49 | 未披露 | 未持股 | 2025-11-17 |
| Barbara Krebs Pohl | 女 | Independent Director | -- | 未披露 | 未持股 | 2025-11-17 |
| 何为无 | 男 | Director | 60 | 966.54万 | 337.79 | 2025-11-17 |
| James Huang | 男 | Non-Executive Chairman | 59 | 15.40万 | 143.50 | 2025-11-17 |
| 吴越 | 男 | Independent Director | 61 | 15.05万 | 未持股 | 2025-11-17 |
| 曾学波 | 男 | Independent Director | 40 | 未披露 | 未持股 | 2025-11-17 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| David Cory | 男 | Chief Executive Officer, Director | 61 | 未披露 | 未持股 | 2025-11-17 |
| 张炜 | 男 | Senior Vice President | 66 | 255.52万 | 23.53 | 2025-11-17 |
| Alexander A. Zukiwski | 男 | Global Chief Medical Officer and Executive Vice President | 67 | 118.14万 | 未持股 | 2025-11-17 |
| 王春华 | 女 | Chief Operation Officer | 53 | 未披露 | 未持股 | 2025-11-17 |
| 钱坤 | 女 | Global Controller, Vice President, Chief Financial Officer | 43 | 未披露 | 未持股 | 2025-11-17 |
| 高玮 | 女 | General Counsel | 43 | 未披露 | 未持股 | 2025-11-17 |
| Huang Hai | 男 | Global Chief Commercial Officer and Executive Vice President | 56 | 未披露 | 未持股 | 2025-11-17 |
| Daniel Lang | 男 | Senior Vice President | 58 | 未披露 | 未持股 | 2025-11-17 |
董事简历
中英对照 | 中文 | 英文- David Cory
-
David Cory自2009年起担任Private Eiger的总裁兼首席执行官，并于2016年3月在本公司担任相同职位。此前，Cory先生于2007年至2008年担任DiObex的首席执行官， 2004年至2006年在Prestwick Pharmaceuticals担任总裁兼首席运营官。Cory先生于2003年在CoTherix担任联合创始人兼代理首席商务官，2000年至2003年在InterMune担任销售和营销高级副总裁。之前，Cory先生在Glaxo, Glaxo Wellcome, and Glaxo Smith Kline的商业运营担任越来越重要的职位。 Cory先生获得University of Cincinnati, College of Pharmacy 药学的理学士学位和University of Maryland University College的工商管理硕士学位。
David Cory, R.Ph.D.,David Cory served as the President and Chief Executive Officer and a member of the Board of Directors of Private Eiger since 2009 until the completion of the Merger in March 2016. Since the completion of the Merger, Mr. Cory has served as our President and Chief Executive Officer and a member of our Board. Previously, Mr. Cory was Chief Executive Officer of DiObex from 2007 to 2008 and President and Chief Operating Officer at Prestwick Pharmaceuticals from 2004 to 2006. Mr. Cory was Co-Founder and Acting Chief Commercial Officer at CoTherix in 2003 and Senior Vice President of Sales and Marketing at InterMune from 2000 to 2003. Previously, Mr. Cory held positions of increasing responsibility in Commercial Operations at Glaxo, Glaxo Wellcome, and Glaxo Smith Kline. Mr. Cory earned a B.S. in Pharmacy from the University of Cincinnati, College of Pharmacy and an M.B.A. from the University of Maryland University College. - David Cory自2009年起担任Private Eiger的总裁兼首席执行官，并于2016年3月在本公司担任相同职位。此前，Cory先生于2007年至2008年担任DiObex的首席执行官， 2004年至2006年在Prestwick Pharmaceuticals担任总裁兼首席运营官。Cory先生于2003年在CoTherix担任联合创始人兼代理首席商务官，2000年至2003年在InterMune担任销售和营销高级副总裁。之前，Cory先生在Glaxo, Glaxo Wellcome, and Glaxo Smith Kline的商业运营担任越来越重要的职位。 Cory先生获得University of Cincinnati, College of Pharmacy 药学的理学士学位和University of Maryland University College的工商管理硕士学位。
- David Cory, R.Ph.D.,David Cory served as the President and Chief Executive Officer and a member of the Board of Directors of Private Eiger since 2009 until the completion of the Merger in March 2016. Since the completion of the Merger, Mr. Cory has served as our President and Chief Executive Officer and a member of our Board. Previously, Mr. Cory was Chief Executive Officer of DiObex from 2007 to 2008 and President and Chief Operating Officer at Prestwick Pharmaceuticals from 2004 to 2006. Mr. Cory was Co-Founder and Acting Chief Commercial Officer at CoTherix in 2003 and Senior Vice President of Sales and Marketing at InterMune from 2000 to 2003. Previously, Mr. Cory held positions of increasing responsibility in Commercial Operations at Glaxo, Glaxo Wellcome, and Glaxo Smith Kline. Mr. Cory earned a B.S. in Pharmacy from the University of Cincinnati, College of Pharmacy and an M.B.A. from the University of Maryland University College.
- Thomas Folinsbee
-
Thomas Folinsbee，是Summit Healthcare Acquisition Corp.的独立董事，拥有超过25年的金融和证券专业经验。自2019年以来，Folinsbee先生一直担任Shanghai Alebund Pharmaceuticals Ltd.（中国制药公司）的业务发展顾问，负责药品inlicensing和outlicensing交易。Folinsbee是徐诺药业有限公司的独立董事之一。 Folinsbee先生是3SBio Inc.战略投资部门的企业发展总监，专注于在加拿大，澳大利亚和日本市场并寻找业务发展机会，包括许可，分销和并购。 Folinsbee先生于2009年加入3SBio，一家生物技术公司，负责管理3SBio的投资者关系活动，并且是管理集团的成员，该集团于2013年5月从纳斯达克退市3SBio，并于2016年6月在香港证券交易所重新上市。此外，自2011年以来，Folinsbee先生一直与日本公司Hisanaga Seisakusho Co. Ltd的董事会合作，在那里他帮助推出了Hisanaga在印度的销售平台，并设计了商业智能系统以支持企业转型。 2001年，Folinsbee先生成立了Optivest Systems Ltd，并开发了专有的研究数据库，以支持机构投资策略。 2006年，Folinsbee先生加入法国巴黎银行的亚洲执行服务台，帮助机构投资者实施统计套利策略和交易后分析。 2008年，他重新加入麦格理证券香港有限公司（Macquarie Equities Hong Kong Limited）的替代策略部门，与股票研究平台合作，打造多空交易策略。 Folinsbee先生曾于1998年至2001年期间在麦格理大学工作。Folinsbee先生于1990年毕业于麦吉尔大学，获得商业学士学位，主修金融和国际业务。
Thomas Folinsbee,has over 25 years of experience as a financial and securities professional. He is the founder of Optivest Canada Ltd, a management consulting company focused on business development and investment research mandates for clients in the healthcare industry. Mr. Folinsbee was previously the director of corporate development for 3Sbio Inc. from 2009 to 2019. From 2017 to 2019, Mr. Folinsbee also served as independent director of Bison Capital Acquisition Corporation and was a member of the audit and compensation committees after the merger with Xynomic Pharmaceuticals. From 2011 to 2016, he also worked for Hisanaga Seisakusho Co. Ltd., a Japanese manufacturing company. Before joining 3Sbio Inc., he also worked at Macquarie Equities, BNP Paribas and Optivest Systems Ltd. Mr. Folinsbee graduated in 1990 from McGill University with a bachelor of commerce degree concentrating in finance and international business and is CFA charter holder. - Thomas Folinsbee，是Summit Healthcare Acquisition Corp.的独立董事，拥有超过25年的金融和证券专业经验。自2019年以来，Folinsbee先生一直担任Shanghai Alebund Pharmaceuticals Ltd.（中国制药公司）的业务发展顾问，负责药品inlicensing和outlicensing交易。Folinsbee是徐诺药业有限公司的独立董事之一。 Folinsbee先生是3SBio Inc.战略投资部门的企业发展总监，专注于在加拿大，澳大利亚和日本市场并寻找业务发展机会，包括许可，分销和并购。 Folinsbee先生于2009年加入3SBio，一家生物技术公司，负责管理3SBio的投资者关系活动，并且是管理集团的成员，该集团于2013年5月从纳斯达克退市3SBio，并于2016年6月在香港证券交易所重新上市。此外，自2011年以来，Folinsbee先生一直与日本公司Hisanaga Seisakusho Co. Ltd的董事会合作，在那里他帮助推出了Hisanaga在印度的销售平台，并设计了商业智能系统以支持企业转型。 2001年，Folinsbee先生成立了Optivest Systems Ltd，并开发了专有的研究数据库，以支持机构投资策略。 2006年，Folinsbee先生加入法国巴黎银行的亚洲执行服务台，帮助机构投资者实施统计套利策略和交易后分析。 2008年，他重新加入麦格理证券香港有限公司（Macquarie Equities Hong Kong Limited）的替代策略部门，与股票研究平台合作，打造多空交易策略。 Folinsbee先生曾于1998年至2001年期间在麦格理大学工作。Folinsbee先生于1990年毕业于麦吉尔大学，获得商业学士学位，主修金融和国际业务。
- Thomas Folinsbee,has over 25 years of experience as a financial and securities professional. He is the founder of Optivest Canada Ltd, a management consulting company focused on business development and investment research mandates for clients in the healthcare industry. Mr. Folinsbee was previously the director of corporate development for 3Sbio Inc. from 2009 to 2019. From 2017 to 2019, Mr. Folinsbee also served as independent director of Bison Capital Acquisition Corporation and was a member of the audit and compensation committees after the merger with Xynomic Pharmaceuticals. From 2011 to 2016, he also worked for Hisanaga Seisakusho Co. Ltd., a Japanese manufacturing company. Before joining 3Sbio Inc., he also worked at Macquarie Equities, BNP Paribas and Optivest Systems Ltd. Mr. Folinsbee graduated in 1990 from McGill University with a bachelor of commerce degree concentrating in finance and international business and is CFA charter holder.
- 苏震波
-
苏震波，在生物科学行业拥有丰富的经验，他是生命科学行业的知名投资人。苏先生目前是Guangzhou Redhill Capital Investment Management Co., Ltd的合伙人，这是一家总部位于广州的领先的生命科学风险投资公司，他于2018年与他人共同创立了Guangzhou Redhill Capital Investment Management Co., Ltd.在加入Redhill之前，他自2013年起担任深圳共享投资医疗基金的管理合伙人。苏先生曾担任生物科学行业多家公司的执行董事，如TCRCure、Genetron、Medprint、尤文图斯、Hocermed、Polyrey、Pandamed、Light Vision和Meyer FSMP。在Su先生开始投资生涯之前，他曾在2007年至2012年期间担任Novartis 旗下公司Alcon中国的董事。在苏先生职业生涯的早期，他曾在Johnson & Johnson的医疗分公司工作。苏先生拥有广东医学院医学学士学位、中山大学公共医疗保健政策和医学法学硕士学位以及芝加哥大学工商管理硕士学位。
Zhenbo Su,has extensive experiences in the bioscience industry, and he has been a well-known investor in the life-science industry. Mr. Su is currently a partner of Guangzhou Redhill Capital Investment Management Co., Ltd, a leading life-science focused venture capital firm based in Guangzhou, which he co-founded in 2018. Prior to Mr. Su's efforts in Redhill, he has served as the managing partner of Shenzhen Shared Investment Medical Fund since 2013. Mr. Su has served as an executive director of multiple companies in bioscience industry, such as TCRCure, Genetron, Medprint, Juventus, Hocermed, Polyrey, Pandamed, Light Vision and Meyer FSMP. Before Mr. Su started his career in investment, he was a director at Alcon China, a Novartis company, from 2007 to 2012. Earlier in Mr. Su's career, he once worked at Johnson & Johnson in medical branch. Mr. Su holds a bachelor's degree in medicine from Guangdong College of Medicine, a master's degree in public healthcare policy and medical law from Sun Yat-sen University, and MBA from the University of Chicago. - 苏震波，在生物科学行业拥有丰富的经验，他是生命科学行业的知名投资人。苏先生目前是Guangzhou Redhill Capital Investment Management Co., Ltd的合伙人，这是一家总部位于广州的领先的生命科学风险投资公司，他于2018年与他人共同创立了Guangzhou Redhill Capital Investment Management Co., Ltd.在加入Redhill之前，他自2013年起担任深圳共享投资医疗基金的管理合伙人。苏先生曾担任生物科学行业多家公司的执行董事，如TCRCure、Genetron、Medprint、尤文图斯、Hocermed、Polyrey、Pandamed、Light Vision和Meyer FSMP。在Su先生开始投资生涯之前，他曾在2007年至2012年期间担任Novartis 旗下公司Alcon中国的董事。在苏先生职业生涯的早期，他曾在Johnson & Johnson的医疗分公司工作。苏先生拥有广东医学院医学学士学位、中山大学公共医疗保健政策和医学法学硕士学位以及芝加哥大学工商管理硕士学位。
- Zhenbo Su,has extensive experiences in the bioscience industry, and he has been a well-known investor in the life-science industry. Mr. Su is currently a partner of Guangzhou Redhill Capital Investment Management Co., Ltd, a leading life-science focused venture capital firm based in Guangzhou, which he co-founded in 2018. Prior to Mr. Su's efforts in Redhill, he has served as the managing partner of Shenzhen Shared Investment Medical Fund since 2013. Mr. Su has served as an executive director of multiple companies in bioscience industry, such as TCRCure, Genetron, Medprint, Juventus, Hocermed, Polyrey, Pandamed, Light Vision and Meyer FSMP. Before Mr. Su started his career in investment, he was a director at Alcon China, a Novartis company, from 2007 to 2012. Earlier in Mr. Su's career, he once worked at Johnson & Johnson in medical branch. Mr. Su holds a bachelor's degree in medicine from Guangdong College of Medicine, a master's degree in public healthcare policy and medical law from Sun Yat-sen University, and MBA from the University of Chicago.
- Barbara Krebs Pohl
-
Barbara Krebs Pohl是生物技术领域备受尊敬的领导者，拥有超过27年的经验，尤其是在开发、商业战略和联盟创建方面。她曾在成功的生物技术公司担任关键职位，包括MorphoSys，在那里她担任首席商务官，并领导了最近诺华以2.9B美元收购MorphoSys的交易。在被诺华收购之前，Dr. Krebs-Pohl在MorphoSys收购和整合Constellation制药以及将felzartamab和izastobart授权给HI-Bio的过程中发挥了关键作用，她在HI-Bio通过渤健以总计1.8B美元收购该公司担任董事。Dr. Krebs-Pohl目前是干细胞研究和再生医学基金会的董事总经理，也是Viopas Venture Consulting的合伙人和董事总经理，在那里她就增长和战略合作伙伴关系为新兴生物技术公司提供建议。
Barbara Krebs Pohl,is a highly respected leader in the biotechnology sector with over 27 years of experience, particularly in development, business strategy and alliance creation. She has held key positions at successful biotechnology companies, including MorphoSys, where she served as Chief Business Officer and led the recent acquisition of MorphoSys by Novartis for $2.9B. Prior to the acquisition by Novartis, Dr. Krebs-Pohl played pivotal roles in the acquisition and integration of Constellation Pharmaceuticals by MorphoSys and the licensing of felzartamab and izastobart to HI-Bio where she served as Director through the acquisition of the company by Biogen for a total of $1.8B.Dr. Krebs-Pohl is currently the Managing Director of the Foundation for Stem Cell Research and Regenerative Medicine, as well as a Partner and Managing Director at Viopas Venture Consulting, where she advises emerging biotechnology companies on growth and strategic partnerships. - Barbara Krebs Pohl是生物技术领域备受尊敬的领导者，拥有超过27年的经验，尤其是在开发、商业战略和联盟创建方面。她曾在成功的生物技术公司担任关键职位，包括MorphoSys，在那里她担任首席商务官，并领导了最近诺华以2.9B美元收购MorphoSys的交易。在被诺华收购之前，Dr. Krebs-Pohl在MorphoSys收购和整合Constellation制药以及将felzartamab和izastobart授权给HI-Bio的过程中发挥了关键作用，她在HI-Bio通过渤健以总计1.8B美元收购该公司担任董事。Dr. Krebs-Pohl目前是干细胞研究和再生医学基金会的董事总经理，也是Viopas Venture Consulting的合伙人和董事总经理，在那里她就增长和战略合作伙伴关系为新兴生物技术公司提供建议。
- Barbara Krebs Pohl,is a highly respected leader in the biotechnology sector with over 27 years of experience, particularly in development, business strategy and alliance creation. She has held key positions at successful biotechnology companies, including MorphoSys, where she served as Chief Business Officer and led the recent acquisition of MorphoSys by Novartis for $2.9B. Prior to the acquisition by Novartis, Dr. Krebs-Pohl played pivotal roles in the acquisition and integration of Constellation Pharmaceuticals by MorphoSys and the licensing of felzartamab and izastobart to HI-Bio where she served as Director through the acquisition of the company by Biogen for a total of $1.8B.Dr. Krebs-Pohl is currently the Managing Director of the Foundation for Stem Cell Research and Regenerative Medicine, as well as a Partner and Managing Director at Viopas Venture Consulting, where she advises emerging biotechnology companies on growth and strategic partnerships.
- 何为无
-
何为无，2012年2月到2013年5月，他是公司的执行主席，此后继续担任董事长。自1995年以来，他曾任OriGene技术公司的首席执行官和董事长。他也是新兴技术合作伙伴的创始人和普通合伙人，一家成立于2000年的生命科学专注于风险基金公司。从1993年到1996年，他是在人类基因组科学的资深科学家。在此之前他是一个马萨诸塞州总医院和梅奥诊所的研究员。他从贝勒医学院获得了他的博士学位，从宾夕法尼亚大学沃顿商学院获得了MBA学位。
Wei Wu He,has served as chairman of the board of directors and CEO of CASI since April 2, 2019. Dr. He served as executive chairman of Company from February 23, 2018 to April 2, 2019, as chairman to the board of directors of Company from May 2013 to February 23, 2018, and as executive chairman from February 2012 to May 2013. Dr. He has been serving as executive chairman of Human Longevity Inc. (a privately-held biotechnology firm specializing in combining DNA sequencing with machine learning) since July 2019. He also is the founder and general partner of Emerging Technology Partners, LLC, a life sciences focused venture fund established in 2000. Dr. He has been involved in founding or funding over 20 biotech companies throughout his career, some of which went on to be acquired by significantly larger firms. In the earlier part of his career, Dr. He was one of the first few scientists at Human Genome Sciences, and prior to that, was a research fellow at Massachusetts General Hospital and Mayo Clinic. Dr. He is an author to more than 25 research publications and inventor of over 30 issued patents. Dr. He received his Ph.D. from Baylor College of Medicine and MBA from The Wharton School of University of Pennsylvania. - 何为无，2012年2月到2013年5月，他是公司的执行主席，此后继续担任董事长。自1995年以来，他曾任OriGene技术公司的首席执行官和董事长。他也是新兴技术合作伙伴的创始人和普通合伙人，一家成立于2000年的生命科学专注于风险基金公司。从1993年到1996年，他是在人类基因组科学的资深科学家。在此之前他是一个马萨诸塞州总医院和梅奥诊所的研究员。他从贝勒医学院获得了他的博士学位，从宾夕法尼亚大学沃顿商学院获得了MBA学位。
- Wei Wu He,has served as chairman of the board of directors and CEO of CASI since April 2, 2019. Dr. He served as executive chairman of Company from February 23, 2018 to April 2, 2019, as chairman to the board of directors of Company from May 2013 to February 23, 2018, and as executive chairman from February 2012 to May 2013. Dr. He has been serving as executive chairman of Human Longevity Inc. (a privately-held biotechnology firm specializing in combining DNA sequencing with machine learning) since July 2019. He also is the founder and general partner of Emerging Technology Partners, LLC, a life sciences focused venture fund established in 2000. Dr. He has been involved in founding or funding over 20 biotech companies throughout his career, some of which went on to be acquired by significantly larger firms. In the earlier part of his career, Dr. He was one of the first few scientists at Human Genome Sciences, and prior to that, was a research fellow at Massachusetts General Hospital and Mayo Clinic. Dr. He is an author to more than 25 research publications and inventor of over 30 issued patents. Dr. He received his Ph.D. from Baylor College of Medicine and MBA from The Wharton School of University of Pennsylvania.
- James Huang
-
James Huang，自2013年4月一直担任公司的董事。2011年6月以来，他担任Kleiner Perkins Caufield Byers China的管理合伙人。KPCB China Fund II的普通合伙人。从2010年到2011年，在加入Kleiner Perkins之前，他是Vivo公司的管理合伙人，一家专门从事生命科学投资的风险投资公司。Huang先生在制药和生物制药行业有超过20年的经验。在这段时间里，他一直担任 Anesiva公司，Tularik公司，GlaxoSmithKline公司，Bristol-Meyers Squibb和ALZA公司的业务发展，销售、营销和研发高级岗位。他获得了斯坦福大学商学院的工商管理硕士学位，和加州大学伯克利的化学工程学士学位。
James Huang has served as a member of Alaunos Therapeutics, Inc.'s Board since July 2020. He served as Chair from January 2021 until February 2021 and Executive Chair from February 2021 to March 29 2022 when he returned to his role as Chair. Mr. Huang joined Kleiner Perkins Caufield & Byers China, or KPCB China, as a managing partner in 2011 and focuses on the firm's life sciences practice. Prior to joining KPCB China, Mr. Huang was a managing partner at Vivo Ventures, a venture capital firm specializing in life sciences investments. Before joining Vivo in 2007 Mr. Huang was president of Anesiva, a biopharmaceutical company focused on pain-management treatments. During his 20-year career in the pharmaceutical and biotech industry, he also held senior roles in business development, sales, marketing and R&D with Tularik Inc. acquired by Amgen, GlaxoSmithKline LLC, Bristol-Myers Squibb and ALZA Corp. acquired by Johnson & Johnson. Mr. Huang is also founding and managing partner of Panacea Venture, a global venture fund focusing on investments in innovative and transformative early and growth stage healthcare and life science companies. Mr. Huang is Chairman of the board at Kindstar Global Beijing Technology, Inc., Windtree Therapeutics, Inc., JHL Biotech, Inc., Tactiva Therapeutics, LLC, and Chime Biologics Limited and Director at CASI Pharmaceuticals Inc. and XW Laboratories Inc. Mr. Huang received an M.B.A. from the Stanford Graduate School of Business and a B.S. degree in chemical engineering from the University of California, Berkeley. - James Huang，自2013年4月一直担任公司的董事。2011年6月以来，他担任Kleiner Perkins Caufield Byers China的管理合伙人。KPCB China Fund II的普通合伙人。从2010年到2011年，在加入Kleiner Perkins之前，他是Vivo公司的管理合伙人，一家专门从事生命科学投资的风险投资公司。Huang先生在制药和生物制药行业有超过20年的经验。在这段时间里，他一直担任 Anesiva公司，Tularik公司，GlaxoSmithKline公司，Bristol-Meyers Squibb和ALZA公司的业务发展，销售、营销和研发高级岗位。他获得了斯坦福大学商学院的工商管理硕士学位，和加州大学伯克利的化学工程学士学位。
- James Huang has served as a member of Alaunos Therapeutics, Inc.'s Board since July 2020. He served as Chair from January 2021 until February 2021 and Executive Chair from February 2021 to March 29 2022 when he returned to his role as Chair. Mr. Huang joined Kleiner Perkins Caufield & Byers China, or KPCB China, as a managing partner in 2011 and focuses on the firm's life sciences practice. Prior to joining KPCB China, Mr. Huang was a managing partner at Vivo Ventures, a venture capital firm specializing in life sciences investments. Before joining Vivo in 2007 Mr. Huang was president of Anesiva, a biopharmaceutical company focused on pain-management treatments. During his 20-year career in the pharmaceutical and biotech industry, he also held senior roles in business development, sales, marketing and R&D with Tularik Inc. acquired by Amgen, GlaxoSmithKline LLC, Bristol-Myers Squibb and ALZA Corp. acquired by Johnson & Johnson. Mr. Huang is also founding and managing partner of Panacea Venture, a global venture fund focusing on investments in innovative and transformative early and growth stage healthcare and life science companies. Mr. Huang is Chairman of the board at Kindstar Global Beijing Technology, Inc., Windtree Therapeutics, Inc., JHL Biotech, Inc., Tactiva Therapeutics, LLC, and Chime Biologics Limited and Director at CASI Pharmaceuticals Inc. and XW Laboratories Inc. Mr. Huang received an M.B.A. from the Stanford Graduate School of Business and a B.S. degree in chemical engineering from the University of California, Berkeley.
- 吴越
-
吴越，自2013年4月他一直是公司的董事。他是Crown Bioscience公司的首席执行官，一家在肿瘤领域拥有超过300名员工的药物发现和临床前研究机构。在2006年，他联合创立了该公司。Crown Bioscience公司之前，从2004年到2006年，亚历克斯是Starvax International公司的首席商务官，一家专注于开发新型治疗药物治疗传染性疾病和癌症的生物制药研发公司。Starvax之前，从2001年到2004年，他事Burrill公司亚洲业务负责人，一家生命科学的风险资本和商业银行。他还共同创立了Unimicro Technologies公司，并担任首席运营官，一个生命科学仪器公司。他在Hoffmann-La公司开始他的职业生涯，他是业务发展和战略规划的经理。他获得了中国复旦大学生物化学学士学位 ，伊利诺斯州大学的生物化学硕士，和加州大学伯克利分校分子细胞生物学博士学位和MBA学位。
Y. Alexander Wu,has been a director of CASI since April 2013. From 2006 to 2017, Dr. Wu was co-founder and chief executive officer of Crown Bioscience, Inc., a drug discovery and pre-clinical research organization in the oncology sector with over 600 employees, which was acquired by JSR for over US$400 million in 2017. Before co-founding Crown Bioscience, Dr. Wu was chief business officer of Starvax International Inc., a biopharmaceutical R&D company focusing on the development of novel therapeutic drugs for the treatment of infectious disease and cancer. Prior to Starvax, he was the head of Asian Operations with Burrill & Company, a life science venture capital and merchant bank. Dr. Wu also co-founded and was chief operating officer of Unimicro Technologies, a life science instrumentation company. He started his career with Hoffmann-La Roche, where he was manager of business development and strategic planning. Dr. Wu obtained his B.S. in biochemistry from Fudan University, China, a M.S. in biochemistry from the University of Illinois, and a Ph.D. in molecular cell biology and MBA from the University of California, Berkeley. - 吴越，自2013年4月他一直是公司的董事。他是Crown Bioscience公司的首席执行官，一家在肿瘤领域拥有超过300名员工的药物发现和临床前研究机构。在2006年，他联合创立了该公司。Crown Bioscience公司之前，从2004年到2006年，亚历克斯是Starvax International公司的首席商务官，一家专注于开发新型治疗药物治疗传染性疾病和癌症的生物制药研发公司。Starvax之前，从2001年到2004年，他事Burrill公司亚洲业务负责人，一家生命科学的风险资本和商业银行。他还共同创立了Unimicro Technologies公司，并担任首席运营官，一个生命科学仪器公司。他在Hoffmann-La公司开始他的职业生涯，他是业务发展和战略规划的经理。他获得了中国复旦大学生物化学学士学位 ，伊利诺斯州大学的生物化学硕士，和加州大学伯克利分校分子细胞生物学博士学位和MBA学位。
- Y. Alexander Wu,has been a director of CASI since April 2013. From 2006 to 2017, Dr. Wu was co-founder and chief executive officer of Crown Bioscience, Inc., a drug discovery and pre-clinical research organization in the oncology sector with over 600 employees, which was acquired by JSR for over US$400 million in 2017. Before co-founding Crown Bioscience, Dr. Wu was chief business officer of Starvax International Inc., a biopharmaceutical R&D company focusing on the development of novel therapeutic drugs for the treatment of infectious disease and cancer. Prior to Starvax, he was the head of Asian Operations with Burrill & Company, a life science venture capital and merchant bank. Dr. Wu also co-founded and was chief operating officer of Unimicro Technologies, a life science instrumentation company. He started his career with Hoffmann-La Roche, where he was manager of business development and strategic planning. Dr. Wu obtained his B.S. in biochemistry from Fudan University, China, a M.S. in biochemistry from the University of Illinois, and a Ph.D. in molecular cell biology and MBA from the University of California, Berkeley.
- 曾学波
-
曾学波先生，1985年5月出生，中国国籍，无境外永久居留权，本科学历。2010年5月至2015年4月任深圳中逸盈泰创业投资有限公司总监；2015年6月至2016年7月任深圳市投控东海投资有限公司副总监；2016年8月至2020年10月任爱奇创业投资管理（深圳）有限公司总监；2020年11月至今历任和谐卓睿（珠海）投资管理有限公司副总裁、董事总经理；2022年1月至2023年9月任杭州先为达生物科技股份有限公司董事；2022年7月至今任四川科伦博泰生物医药股份有限公司董事；2022年9月至今任上海南方模式生物科技股份有限公司董事；2022年12月至今任凯瑞斯德生化（苏州）有限公司董事；2023年2月至今任江西隆莱生物制药有限公司董事；2023年2月至今任苏州鹏旭医药科技有限公司董事；2023年3月至今任CASI Pharmaceuticals,Inc董事；2023年4月至今任浙江艾比奥健康科技有限公司董事；2023年11月至今任ZenCore（Cayman）Limited董事；2024年5月至今任成都普康唯新生物科技有限公司董事；2024年11月至今任广东东阳光药业股份有限公司董事；2017年12月至今任安徽申兰华色材股份有限公司董事。
Xuebo Zeng,has been an executive director at IDG Capital since 2016, focusing on the investment in drug development, biotechnology, diagnostic devices and medical services. Mr. Zeng started his career in quality control department of Guilin Pharma in 2008 and soon became an investment manager specialized in life sciences investments. Prior to joining IDG Capital, he worked as an investment manager in two other famous private equity firms in China from 2010 to 2016. Mr. Zeng is a member of the board of directors of a number of private and listed companies, including Shanghai Model Organisms and Kelun-Biotech. Mr. Zeng received a bachelor's degree in pharmacy from Qinghai Nationalities University, China. - 曾学波先生，1985年5月出生，中国国籍，无境外永久居留权，本科学历。2010年5月至2015年4月任深圳中逸盈泰创业投资有限公司总监；2015年6月至2016年7月任深圳市投控东海投资有限公司副总监；2016年8月至2020年10月任爱奇创业投资管理（深圳）有限公司总监；2020年11月至今历任和谐卓睿（珠海）投资管理有限公司副总裁、董事总经理；2022年1月至2023年9月任杭州先为达生物科技股份有限公司董事；2022年7月至今任四川科伦博泰生物医药股份有限公司董事；2022年9月至今任上海南方模式生物科技股份有限公司董事；2022年12月至今任凯瑞斯德生化（苏州）有限公司董事；2023年2月至今任江西隆莱生物制药有限公司董事；2023年2月至今任苏州鹏旭医药科技有限公司董事；2023年3月至今任CASI Pharmaceuticals,Inc董事；2023年4月至今任浙江艾比奥健康科技有限公司董事；2023年11月至今任ZenCore（Cayman）Limited董事；2024年5月至今任成都普康唯新生物科技有限公司董事；2024年11月至今任广东东阳光药业股份有限公司董事；2017年12月至今任安徽申兰华色材股份有限公司董事。
- Xuebo Zeng,has been an executive director at IDG Capital since 2016, focusing on the investment in drug development, biotechnology, diagnostic devices and medical services. Mr. Zeng started his career in quality control department of Guilin Pharma in 2008 and soon became an investment manager specialized in life sciences investments. Prior to joining IDG Capital, he worked as an investment manager in two other famous private equity firms in China from 2010 to 2016. Mr. Zeng is a member of the board of directors of a number of private and listed companies, including Shanghai Model Organisms and Kelun-Biotech. Mr. Zeng received a bachelor's degree in pharmacy from Qinghai Nationalities University, China.
高管简历
中英对照 | 中文 | 英文- David Cory
David Cory自2009年起担任Private Eiger的总裁兼首席执行官，并于2016年3月在本公司担任相同职位。此前，Cory先生于2007年至2008年担任DiObex的首席执行官， 2004年至2006年在Prestwick Pharmaceuticals担任总裁兼首席运营官。Cory先生于2003年在CoTherix担任联合创始人兼代理首席商务官，2000年至2003年在InterMune担任销售和营销高级副总裁。之前，Cory先生在Glaxo, Glaxo Wellcome, and Glaxo Smith Kline的商业运营担任越来越重要的职位。 Cory先生获得University of Cincinnati, College of Pharmacy 药学的理学士学位和University of Maryland University College的工商管理硕士学位。
David Cory, R.Ph.D.,David Cory served as the President and Chief Executive Officer and a member of the Board of Directors of Private Eiger since 2009 until the completion of the Merger in March 2016. Since the completion of the Merger, Mr. Cory has served as our President and Chief Executive Officer and a member of our Board. Previously, Mr. Cory was Chief Executive Officer of DiObex from 2007 to 2008 and President and Chief Operating Officer at Prestwick Pharmaceuticals from 2004 to 2006. Mr. Cory was Co-Founder and Acting Chief Commercial Officer at CoTherix in 2003 and Senior Vice President of Sales and Marketing at InterMune from 2000 to 2003. Previously, Mr. Cory held positions of increasing responsibility in Commercial Operations at Glaxo, Glaxo Wellcome, and Glaxo Smith Kline. Mr. Cory earned a B.S. in Pharmacy from the University of Cincinnati, College of Pharmacy and an M.B.A. from the University of Maryland University College.- David Cory自2009年起担任Private Eiger的总裁兼首席执行官，并于2016年3月在本公司担任相同职位。此前，Cory先生于2007年至2008年担任DiObex的首席执行官， 2004年至2006年在Prestwick Pharmaceuticals担任总裁兼首席运营官。Cory先生于2003年在CoTherix担任联合创始人兼代理首席商务官，2000年至2003年在InterMune担任销售和营销高级副总裁。之前，Cory先生在Glaxo, Glaxo Wellcome, and Glaxo Smith Kline的商业运营担任越来越重要的职位。 Cory先生获得University of Cincinnati, College of Pharmacy 药学的理学士学位和University of Maryland University College的工商管理硕士学位。
- David Cory, R.Ph.D.,David Cory served as the President and Chief Executive Officer and a member of the Board of Directors of Private Eiger since 2009 until the completion of the Merger in March 2016. Since the completion of the Merger, Mr. Cory has served as our President and Chief Executive Officer and a member of our Board. Previously, Mr. Cory was Chief Executive Officer of DiObex from 2007 to 2008 and President and Chief Operating Officer at Prestwick Pharmaceuticals from 2004 to 2006. Mr. Cory was Co-Founder and Acting Chief Commercial Officer at CoTherix in 2003 and Senior Vice President of Sales and Marketing at InterMune from 2000 to 2003. Previously, Mr. Cory held positions of increasing responsibility in Commercial Operations at Glaxo, Glaxo Wellcome, and Glaxo Smith Kline. Mr. Cory earned a B.S. in Pharmacy from the University of Cincinnati, College of Pharmacy and an M.B.A. from the University of Maryland University College.
- 张炜
张炜于2018年9月加入Casi Pharmaceuticals, Inc.，担任CASI Beijing Pharmaceuticals Co., Ltd.（现称CASI Pharmaceuticals （China） Co., Ltd.（简称CASI China））的总裁，CASI Pharmaceuticals （China） Co., Ltd.是Casi Pharmaceuticals, Inc.的子公司，2019年9月，他升任总裁，在美国医疗保健和生物制药行业拥有20多年的管理经验。亚太地区和中国。在加入北京办事处之前，张炜是Novartis Group（中国）的副总裁、公共事务和企业责任负责人，专注于公共事务/公共关系战略，包括启动Novartis Group （China）政策，重点关注国家医疗产品管理局（NMPA）的新药审批改革、知识产权保护，通用质量一致性评估和生物仿制药新法规。2021-2016年，张炜担任Sandoz Pharmaceutical（China）首席执行官。张炜还曾在美国和亚太地区的Bayer医疗和Baxter International Corporation担任高管领导职务。张炜拥有中国科学技术大学核物理学士和硕士学位，加州大学洛杉矶分校（UCLA）市场营销/金融MBA学位，并在犹他大学接受政治学博士培训。
Wei Zhang,joined CASI in September 2018 as president of CASI (Beijing) Pharmaceuticals Co., Ltd., now known as CASI Pharmaceuticals (China) Co., Ltd. ("CASI China"), which is a subsidiary of CASI, and his role expanded to president and principal financial officer of CASI in September 2019. Mr. Zhang was re-appointed as a Senior Vice President in September 2024 due to Casi Pharmaceuticals, Inc. adjustment to the management positions and removal of president role. Mr. Zhang has more than 20 years management experience in the healthcare and biopharmaceutical industries in the U.S., Asia Pacific, and China. Prior to joining CASI's Beijing office, Mr. Zhang was vice president, head of public affairs and corporate responsibility at Novartis Group (China) focusing on the public affairs/public relations strategy including initiating Novartis' China policy focusing on NMPA new drug approval reform, IP protection, generic quality consistency evaluation and new regulations on biosimilars. From 2011 to 2016, he was chief executive officer of Sandoz Pharmaceutical (China), a Novartis Company. Mr. Zhang has also held executive leadership roles with Bayer Healthcare and Baxter International Corporation in the U.S. and Asia Pacific. He holds a bachelor and master degree in nuclear physics from University of Science & Technology of China, an MBA in marketing/finance from the University of California at Los Angeles (UCLA), and received Ph.D. training in political science from University of Utah.- 张炜于2018年9月加入Casi Pharmaceuticals, Inc.，担任CASI Beijing Pharmaceuticals Co., Ltd.（现称CASI Pharmaceuticals （China） Co., Ltd.（简称CASI China））的总裁，CASI Pharmaceuticals （China） Co., Ltd.是Casi Pharmaceuticals, Inc.的子公司，2019年9月，他升任总裁，在美国医疗保健和生物制药行业拥有20多年的管理经验。亚太地区和中国。在加入北京办事处之前，张炜是Novartis Group（中国）的副总裁、公共事务和企业责任负责人，专注于公共事务/公共关系战略，包括启动Novartis Group （China）政策，重点关注国家医疗产品管理局（NMPA）的新药审批改革、知识产权保护，通用质量一致性评估和生物仿制药新法规。2021-2016年，张炜担任Sandoz Pharmaceutical（China）首席执行官。张炜还曾在美国和亚太地区的Bayer医疗和Baxter International Corporation担任高管领导职务。张炜拥有中国科学技术大学核物理学士和硕士学位，加州大学洛杉矶分校（UCLA）市场营销/金融MBA学位，并在犹他大学接受政治学博士培训。
- Wei Zhang,joined CASI in September 2018 as president of CASI (Beijing) Pharmaceuticals Co., Ltd., now known as CASI Pharmaceuticals (China) Co., Ltd. ("CASI China"), which is a subsidiary of CASI, and his role expanded to president and principal financial officer of CASI in September 2019. Mr. Zhang was re-appointed as a Senior Vice President in September 2024 due to Casi Pharmaceuticals, Inc. adjustment to the management positions and removal of president role. Mr. Zhang has more than 20 years management experience in the healthcare and biopharmaceutical industries in the U.S., Asia Pacific, and China. Prior to joining CASI's Beijing office, Mr. Zhang was vice president, head of public affairs and corporate responsibility at Novartis Group (China) focusing on the public affairs/public relations strategy including initiating Novartis' China policy focusing on NMPA new drug approval reform, IP protection, generic quality consistency evaluation and new regulations on biosimilars. From 2011 to 2016, he was chief executive officer of Sandoz Pharmaceutical (China), a Novartis Company. Mr. Zhang has also held executive leadership roles with Bayer Healthcare and Baxter International Corporation in the U.S. and Asia Pacific. He holds a bachelor and master degree in nuclear physics from University of Science & Technology of China, an MBA in marketing/finance from the University of California at Los Angeles (UCLA), and received Ph.D. training in political science from University of Utah.
- Alexander A. Zukiwski
Alexander A. Zukiwski于2017年4月加入公司，担任首席医疗官。在加入公司之前，Alexander A.Zukiwski是Arno Therapeutics的首席执行官和首席医疗官，自2014年起担任Arno Theapeutics“Arno”的董事。在2007年加入Arno之前，Alexander A.Zukiwski担任MedImmune LLC（“MedImmunce”）的首席医疗官和临床研究执行副总裁。在加入MedImmune之前，Alexander A.Zukiwski在强生公司（“强生”）的医疗事务和强生制药研发有限责任公司（“J&JPRD”）的临床开发职能部门担任多个职位，职责日益增加；Centocor研发和Ortho Biotech。在加入强生之前，Alexander A.Zukiwski曾在Hoffmann LaRoche、Glaxo Wellcome和Rhone Poulenc Rorer等制药公司担任临床肿瘤学职位。Alexander A.Zukiwski在全球药物开发方面拥有超过21年的经验，并支持许多成功的肿瘤治疗剂的临床评估和注册，包括Taxotere、Xeloda、Procrit/Eprex、Velcade、Yondelis和Doxil。Alexander A.Zukiwski曾担任Gem Pharmaceuticals，LLC医疗顾问委员会成员，并担任Ambit Biosciences Corporation董事。Alexander A.Zukiwski拥有阿尔伯塔大学药学学士学位和卡尔加里大学医学博士学位。亚历山大·祖基夫斯基（Alexander A.Zukowski）在俄亥俄州阿克伦的圣托马斯医院医疗中心（St.Thomas Hospital Medical Center）和德克萨斯大学医学博士安德森癌症中心（University of Texas MD Anderson Cancer Center）进行了研究生培训。
Alexander A. Zukiwski,joined CASI in April of 2017 as chief medical officer, and he currently serves as executive vice president and chief medical officer. Prior to joining the Company, Dr. Zukiwski was chief executive officer and chief medical officer of Arno Therapeutics and has been a director of Arno Therapeutics ("Arno") since 2014. At Arno, his responsibilities included leading the clinical development and regulatory affairs teams to support the company's pipeline. Prior to joining Arno in 2007, Dr. Zukiwski served as chief medical officer and executive vice president of clinical research at MedImmune LLC ("MedImmune"). Prior to MedImmune, Dr. Zukiwski held several roles of increasing responsibility at Johnson & Johnson's ("J&J") medical affairs and clinical development functions at Johnson & Johnson Pharmaceutical Research & Development LLC ("J&JPRD"), Centocor R&D and Ortho Biotech. Before joining J&J, he served in clinical oncology positions at pharmaceutical companies such as Hoffmann-LaRoche, Glaxo Wellcome and Rhone-Poulenc Rorer. Dr. Zukiwski has more than 21 years of experience in global drug development and supported the clinical evaluation and registration of many successful oncology therapeutic agents, including Taxotere, Xeloda, Procrit/Eprex, Velcade, Yondelis, and Doxil. He previously served as a member of medical advisory board at Gem Pharmaceuticals, LLC and served as a director of Ambit Biosciences Corporation. Dr. Zukiwski holds a bachelor's degree in pharmacy from the University of Alberta and a Doctor of Medicine degree from the University of Calgary. He conducted his post-graduate training at St. Thomas Hospital Medical Center in Akron, Ohio and the University of Texas MD Anderson Cancer Center.- Alexander A. Zukiwski于2017年4月加入公司，担任首席医疗官。在加入公司之前，Alexander A.Zukiwski是Arno Therapeutics的首席执行官和首席医疗官，自2014年起担任Arno Theapeutics“Arno”的董事。在2007年加入Arno之前，Alexander A.Zukiwski担任MedImmune LLC（“MedImmunce”）的首席医疗官和临床研究执行副总裁。在加入MedImmune之前，Alexander A.Zukiwski在强生公司（“强生”）的医疗事务和强生制药研发有限责任公司（“J&JPRD”）的临床开发职能部门担任多个职位，职责日益增加；Centocor研发和Ortho Biotech。在加入强生之前，Alexander A.Zukiwski曾在Hoffmann LaRoche、Glaxo Wellcome和Rhone Poulenc Rorer等制药公司担任临床肿瘤学职位。Alexander A.Zukiwski在全球药物开发方面拥有超过21年的经验，并支持许多成功的肿瘤治疗剂的临床评估和注册，包括Taxotere、Xeloda、Procrit/Eprex、Velcade、Yondelis和Doxil。Alexander A.Zukiwski曾担任Gem Pharmaceuticals，LLC医疗顾问委员会成员，并担任Ambit Biosciences Corporation董事。Alexander A.Zukiwski拥有阿尔伯塔大学药学学士学位和卡尔加里大学医学博士学位。亚历山大·祖基夫斯基（Alexander A.Zukowski）在俄亥俄州阿克伦的圣托马斯医院医疗中心（St.Thomas Hospital Medical Center）和德克萨斯大学医学博士安德森癌症中心（University of Texas MD Anderson Cancer Center）进行了研究生培训。
- Alexander A. Zukiwski,joined CASI in April of 2017 as chief medical officer, and he currently serves as executive vice president and chief medical officer. Prior to joining the Company, Dr. Zukiwski was chief executive officer and chief medical officer of Arno Therapeutics and has been a director of Arno Therapeutics ("Arno") since 2014. At Arno, his responsibilities included leading the clinical development and regulatory affairs teams to support the company's pipeline. Prior to joining Arno in 2007, Dr. Zukiwski served as chief medical officer and executive vice president of clinical research at MedImmune LLC ("MedImmune"). Prior to MedImmune, Dr. Zukiwski held several roles of increasing responsibility at Johnson & Johnson's ("J&J") medical affairs and clinical development functions at Johnson & Johnson Pharmaceutical Research & Development LLC ("J&JPRD"), Centocor R&D and Ortho Biotech. Before joining J&J, he served in clinical oncology positions at pharmaceutical companies such as Hoffmann-LaRoche, Glaxo Wellcome and Rhone-Poulenc Rorer. Dr. Zukiwski has more than 21 years of experience in global drug development and supported the clinical evaluation and registration of many successful oncology therapeutic agents, including Taxotere, Xeloda, Procrit/Eprex, Velcade, Yondelis, and Doxil. He previously served as a member of medical advisory board at Gem Pharmaceuticals, LLC and served as a director of Ambit Biosciences Corporation. Dr. Zukiwski holds a bachelor's degree in pharmacy from the University of Alberta and a Doctor of Medicine degree from the University of Calgary. He conducted his post-graduate training at St. Thomas Hospital Medical Center in Akron, Ohio and the University of Texas MD Anderson Cancer Center.
- 王春华
王春华自2017年起担任CASI的首席运营官。王女士负责公司后台运营和生产现场管理，主管人力资源、IT、通信、政务、法律、法规事务、研发等工作。在加入CASI之前，王女士于2015年至2017年担任Vcanbio的副总裁。在加入Vcanbio之前，王女士曾于2014年至2015年担任Marsh & McLennan公司的副总裁。2011年至2014年，王女士在Schneider Electric SA.担任人力资源总监。在加入Schneider Electric SA之前，王女士于2002年至2010年在Tycoman Co., Ltd.担任副总裁，在此之前，王女士是Tyco Healthcare的人力资源总监。在王女士职业生涯的早期，她曾在国有企业从事人力资源领域的工作。王女士在中国东北大学获得冶金学学士学位，在中国人民大学获得经济学硕士学位。
Chunhua Wang,has been chief operation officer of CASI since 2017. Ms. Wang is responsible for the Company's back-office operation and manufacturing site management and is account for human resources, IT, communication, government affairs, legal, regulatory affairs, R&D, etc. Prior to joining CASI, Ms. Wang was the vice president of Vcanbio from 2015 to 2017. Before she joined Vcanbio, Ms. Wang was the VP at Marsh & McLennan Companies from 2014 to 2015. From 2011 to 2014, Ms. Wang served as the HR director at Schneider Electric SA. Prior her experience in Schneider, Ms. Wang was the vice president at Tycoman Co., Ltd. a medical device company, from 2002 to 2010, and before that, Ms. Wang was the HR director at Tyco Healthcare. Earlier in Ms. Wang's career, she worked at state-owned enterprises in human resource field. Ms. Wang received the bachelor's degree in Metallurgy from China Northeastern University, and master's degree in economics from Renmin University of China.- 王春华自2017年起担任CASI的首席运营官。王女士负责公司后台运营和生产现场管理，主管人力资源、IT、通信、政务、法律、法规事务、研发等工作。在加入CASI之前，王女士于2015年至2017年担任Vcanbio的副总裁。在加入Vcanbio之前，王女士曾于2014年至2015年担任Marsh & McLennan公司的副总裁。2011年至2014年，王女士在Schneider Electric SA.担任人力资源总监。在加入Schneider Electric SA之前，王女士于2002年至2010年在Tycoman Co., Ltd.担任副总裁，在此之前，王女士是Tyco Healthcare的人力资源总监。在王女士职业生涯的早期，她曾在国有企业从事人力资源领域的工作。王女士在中国东北大学获得冶金学学士学位，在中国人民大学获得经济学硕士学位。
- Chunhua Wang,has been chief operation officer of CASI since 2017. Ms. Wang is responsible for the Company's back-office operation and manufacturing site management and is account for human resources, IT, communication, government affairs, legal, regulatory affairs, R&D, etc. Prior to joining CASI, Ms. Wang was the vice president of Vcanbio from 2015 to 2017. Before she joined Vcanbio, Ms. Wang was the VP at Marsh & McLennan Companies from 2014 to 2015. From 2011 to 2014, Ms. Wang served as the HR director at Schneider Electric SA. Prior her experience in Schneider, Ms. Wang was the vice president at Tycoman Co., Ltd. a medical device company, from 2002 to 2010, and before that, Ms. Wang was the HR director at Tyco Healthcare. Earlier in Ms. Wang's career, she worked at state-owned enterprises in human resource field. Ms. Wang received the bachelor's degree in Metallurgy from China Northeastern University, and master's degree in economics from Renmin University of China.
- 钱坤
钱坤，自2022年1月起担任CASI全球财务总监兼副总裁。她负责所有公司财务职能，包括公司财务总监、财务规划和分析、财务、税务和区域财务活动。在加入CASI之前，她于2021年至2022年在Guazi.com担任财务总监。在此之前，她曾于2016-2020年在Wanda Sports Group旗下产业集团万达体育集团担任全球财务总监，并于2019年在纳斯达克完成首次公开募股。2014年至2016年任职于Weichai Group国际金融部。在2014年之前，她是一名高级审计经理，在普华永道钟田律师事务所北京办事处和普华永道新加坡办事处工作了近10年。钱女士在对外经济贸易大学获得管理学学士学位。她是新罕布什尔州的注册会计师，也是美国注册会计师协会的会员。钱女士还具有中国注册会计师和加拿大特许专业会计师的资格。
Kun Qian,has been CASI's global controller and vice president since January 2022. She is responsible for all corporate finance functions, including corporate controller, financial planning and analysis, treasury, tax, and regional finance activities. Prior to joining CASI, she served as financial director in Guazi.com from 2021 to 2022. Prior to that, she served as global controller at Wanda Sports Group, an industry group of Wanda Group, from 2016-2020 and completed its initial public offering in Nasdaq in 2019. She worked in international finance department at Weichai Group from 2014 to 2016. Prior to 2014, she was a senior audit manager and spent nearly 10 years with PricewaterhouseCoopers Zhong Tian LLP, Beijing office and PricewaterhouseCoopers, Singapore office. Ms. Qian received a bachelor's degree in Management from University of International Business and Economics. She is a Certified Public Accountant in the State of New Hampshire and a member of American Institute of Certified Public Accountants. Ms. Qian also qualifies as a Certified Public Accountant in China and a Chartered Professional Accountant in Canada.- 钱坤，自2022年1月起担任CASI全球财务总监兼副总裁。她负责所有公司财务职能，包括公司财务总监、财务规划和分析、财务、税务和区域财务活动。在加入CASI之前，她于2021年至2022年在Guazi.com担任财务总监。在此之前，她曾于2016-2020年在Wanda Sports Group旗下产业集团万达体育集团担任全球财务总监，并于2019年在纳斯达克完成首次公开募股。2014年至2016年任职于Weichai Group国际金融部。在2014年之前，她是一名高级审计经理，在普华永道钟田律师事务所北京办事处和普华永道新加坡办事处工作了近10年。钱女士在对外经济贸易大学获得管理学学士学位。她是新罕布什尔州的注册会计师，也是美国注册会计师协会的会员。钱女士还具有中国注册会计师和加拿大特许专业会计师的资格。
- Kun Qian,has been CASI's global controller and vice president since January 2022. She is responsible for all corporate finance functions, including corporate controller, financial planning and analysis, treasury, tax, and regional finance activities. Prior to joining CASI, she served as financial director in Guazi.com from 2021 to 2022. Prior to that, she served as global controller at Wanda Sports Group, an industry group of Wanda Group, from 2016-2020 and completed its initial public offering in Nasdaq in 2019. She worked in international finance department at Weichai Group from 2014 to 2016. Prior to 2014, she was a senior audit manager and spent nearly 10 years with PricewaterhouseCoopers Zhong Tian LLP, Beijing office and PricewaterhouseCoopers, Singapore office. Ms. Qian received a bachelor's degree in Management from University of International Business and Economics. She is a Certified Public Accountant in the State of New Hampshire and a member of American Institute of Certified Public Accountants. Ms. Qian also qualifies as a Certified Public Accountant in China and a Chartered Professional Accountant in Canada.
- 高玮
高玮，自2023年1月起担任CASI的总法律顾问。在担任现职之前，Gao女士自2020年12月起担任法律总监。在加入CASI之前，高女士于2017年至2020年在Medtronic Beijing担任法务经理。此前，高女士曾于2012年至2017年担任Syngenta Beijing的法律顾问。2006年至2007年和2010年至2012年，高女士在Caterpillar担任法律顾问和高级顾问。在她职业生涯的早期，高女士曾于2008年至2010年在Commerce & Finance律师事务所担任诉讼律师，专门处理国际商业纠纷。2005年至2006年，高女士在Guo & Partners Attorneys At Law担任法律助理，开始了她的法律生涯。高女士在吉林大学获得经济法学士学位，在曼彻斯特大学获得国际商法法学硕士学位。
Wei Gao,has been serving as CASI's general counsel since January 2023. Prior to her current position, Ms. Gao was legal director since December 2020. Prior to joining CASI, Ms. Gao served as legal manager in Medtronic Beijing from 2017 to 2020. Earlier, Ms. Gao was a legal counsel of Syngenta Beijing from 2012 to 2017. From 2006 to 2007, and from 2010 to 2012, Ms. Gao served as legal consultant and senior consultant in Caterpillar. Earlier in her career, Ms. Gao worked as a litigation lawyer specializing international business dispute resolution in Commerce & Finance Law Offices from 2008 to 2010. Ms. Gao started her legal career as a legal assistant in Guo & Partners Attorneys At Law from 2005 to 2006. Ms. Gao received her bachelor's degree in Economic Law from Jilin University and LL.M. degree in International Business Law from the University of Manchester.- 高玮，自2023年1月起担任CASI的总法律顾问。在担任现职之前，Gao女士自2020年12月起担任法律总监。在加入CASI之前，高女士于2017年至2020年在Medtronic Beijing担任法务经理。此前，高女士曾于2012年至2017年担任Syngenta Beijing的法律顾问。2006年至2007年和2010年至2012年，高女士在Caterpillar担任法律顾问和高级顾问。在她职业生涯的早期，高女士曾于2008年至2010年在Commerce & Finance律师事务所担任诉讼律师，专门处理国际商业纠纷。2005年至2006年，高女士在Guo & Partners Attorneys At Law担任法律助理，开始了她的法律生涯。高女士在吉林大学获得经济法学士学位，在曼彻斯特大学获得国际商法法学硕士学位。
- Wei Gao,has been serving as CASI's general counsel since January 2023. Prior to her current position, Ms. Gao was legal director since December 2020. Prior to joining CASI, Ms. Gao served as legal manager in Medtronic Beijing from 2017 to 2020. Earlier, Ms. Gao was a legal counsel of Syngenta Beijing from 2012 to 2017. From 2006 to 2007, and from 2010 to 2012, Ms. Gao served as legal consultant and senior consultant in Caterpillar. Earlier in her career, Ms. Gao worked as a litigation lawyer specializing international business dispute resolution in Commerce & Finance Law Offices from 2008 to 2010. Ms. Gao started her legal career as a legal assistant in Guo & Partners Attorneys At Law from 2005 to 2006. Ms. Gao received her bachelor's degree in Economic Law from Jilin University and LL.M. degree in International Business Law from the University of Manchester.
- Huang Hai
Huang Hai，自2024年1月以来担任Casi Pharmaceuticals, Inc.（执行副总裁）。Huang先生负责CASI全球商业化战略的发展，监督全球业务体系的建立，以及市场扩展和战略业务合作关系的管理。在加入Casi Pharmaceuticals, Inc.之前，Huang先生曾担任Fosun Kite Biotechnology Co., Ltd.的首席执行官。Huang先生于2016年至2020年在辉瑞中国工作，担任过基础业务的总经理、首席市场官/副总裁以及后来的首席运营官。从2013年至2016年，Huang先生在美敦力担任大中华区糖尿病业务部的总经理。从2011年至2013年，他在赛诺菲-安万特担任糖尿病业务部的全国销售负责人。Huang先生于1997年加入辉瑞，并担任销售总监至2010年。Huang先生目前还担任上海CGT特别委员会的执行董事，以及上海产学研专家组委员会的成员。Huang先生获得了北京大学的生物MBA学位和兰州大学的生物化学本科学位。
Huang Hai,has been global chief commercial officer (executive vice president) of CASI since January 2024. Mr. Huang leads the development of CASI's global commercialization strategy, overseeing the establishment of a global business system, and managing market expansion and strategic business partnerships. Prior to joining Casi Pharmaceuticals, Inc. , Mr. Huang served as the chief executive officer of Fosun Kite Biotechnology Co., Ltd. Mr. Huang worked with Pfizer China from 2016 to 2020, acting as general manager of essential business, chief marketing officer/vice president and then chief operating officer of essential business. From 2013 to 2016, Mr. Huang worked with Medtronic as a general manager of Diabetes BU for greater China region. From 2011 to 2013, Mr. Huang worked with Sanofi Aventis as a national sales leader of Diabetes BU. Mr. Huang joined Pfizer in 1997 and worked as sales director till 2010. Mr. Huang currently also holds positions as the Executive Director of the Shanghai CGT Special Committee and a member of the Shanghai Industry-Academia-Research Expert Group Committee. Mr. Huang received the Bi-MBA from Peking University and an undergraduate degree in Biochemistry from Lanzhou University.- Huang Hai，自2024年1月以来担任Casi Pharmaceuticals, Inc.（执行副总裁）。Huang先生负责CASI全球商业化战略的发展，监督全球业务体系的建立，以及市场扩展和战略业务合作关系的管理。在加入Casi Pharmaceuticals, Inc.之前，Huang先生曾担任Fosun Kite Biotechnology Co., Ltd.的首席执行官。Huang先生于2016年至2020年在辉瑞中国工作，担任过基础业务的总经理、首席市场官/副总裁以及后来的首席运营官。从2013年至2016年，Huang先生在美敦力担任大中华区糖尿病业务部的总经理。从2011年至2013年，他在赛诺菲-安万特担任糖尿病业务部的全国销售负责人。Huang先生于1997年加入辉瑞，并担任销售总监至2010年。Huang先生目前还担任上海CGT特别委员会的执行董事，以及上海产学研专家组委员会的成员。Huang先生获得了北京大学的生物MBA学位和兰州大学的生物化学本科学位。
- Huang Hai,has been global chief commercial officer (executive vice president) of CASI since January 2024. Mr. Huang leads the development of CASI's global commercialization strategy, overseeing the establishment of a global business system, and managing market expansion and strategic business partnerships. Prior to joining Casi Pharmaceuticals, Inc. , Mr. Huang served as the chief executive officer of Fosun Kite Biotechnology Co., Ltd. Mr. Huang worked with Pfizer China from 2016 to 2020, acting as general manager of essential business, chief marketing officer/vice president and then chief operating officer of essential business. From 2013 to 2016, Mr. Huang worked with Medtronic as a general manager of Diabetes BU for greater China region. From 2011 to 2013, Mr. Huang worked with Sanofi Aventis as a national sales leader of Diabetes BU. Mr. Huang joined Pfizer in 1997 and worked as sales director till 2010. Mr. Huang currently also holds positions as the Executive Director of the Shanghai CGT Special Committee and a member of the Shanghai Industry-Academia-Research Expert Group Committee. Mr. Huang received the Bi-MBA from Peking University and an undergraduate degree in Biochemistry from Lanzhou University.
- Daniel Lang
Daniel Lang，于2024年7月加入CASI，担任CASI Pharmaceuticals， Inc.的首席财务官兼高级副总裁。Lang博士拥有超过30年的医生、科学家、投资者和生物技术高管经验。他是UCSF培训的心脏病专家，随后在Farallon Capital担任投资组合经理和RS Investments Value Group首席投资官，拥有20年的投资经验。最近，他是Athenex细胞治疗部门的总裁，领导NKT细胞平台的临床开发。他在加州大学旧金山分校和格莱斯顿心血管研究所完成了心脏病学研究。他获得了Cornell大学Medical College的医学博士学位和Cornell大学的化学学士学位。
Daniel Lang,joined CASI in July 2024 as Chief Financial Officer and Senior Vice President of CASI Pharmaceuticals, Inc. Dr. Lang has more than 30 years of experience as a physician scientist, investor, and biotech executive. He is a cardiologist by training from UCSF, followed by 20 years of investment experience as a portfolio manager at Farallon Capital and Chief Investment Officer at RS Investments Value Group. Most recently, he was the President of Athenex cell therapy division and led clinical development of the NKT cell platform. He completed his cardiology fellowship at UCSF and Gladstone Cardiovascular Research Institute. He obtained his MD degree from Cornell University Medical College and BA in Chemistry from Cornell University.- Daniel Lang，于2024年7月加入CASI，担任CASI Pharmaceuticals， Inc.的首席财务官兼高级副总裁。Lang博士拥有超过30年的医生、科学家、投资者和生物技术高管经验。他是UCSF培训的心脏病专家，随后在Farallon Capital担任投资组合经理和RS Investments Value Group首席投资官，拥有20年的投资经验。最近，他是Athenex细胞治疗部门的总裁，领导NKT细胞平台的临床开发。他在加州大学旧金山分校和格莱斯顿心血管研究所完成了心脏病学研究。他获得了Cornell大学Medical College的医学博士学位和Cornell大学的化学学士学位。
- Daniel Lang,joined CASI in July 2024 as Chief Financial Officer and Senior Vice President of CASI Pharmaceuticals, Inc. Dr. Lang has more than 30 years of experience as a physician scientist, investor, and biotech executive. He is a cardiologist by training from UCSF, followed by 20 years of investment experience as a portfolio manager at Farallon Capital and Chief Investment Officer at RS Investments Value Group. Most recently, he was the President of Athenex cell therapy division and led clinical development of the NKT cell platform. He completed his cardiology fellowship at UCSF and Gladstone Cardiovascular Research Institute. He obtained his MD degree from Cornell University Medical College and BA in Chemistry from Cornell University.